Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments

[1]  S. Gupta,et al.  Treatment‐related mortality in children with acute lymphoblastic leukemia in Central America , 2011, Cancer.

[2]  E. Lopez-Lopez,et al.  Polymorphisms of the SLCO1B1 gene predict methotrexate‐related toxicity in childhood acute lymphoblastic leukemia , 2011, Pediatric blood & cancer.

[3]  S. Lipshultz,et al.  Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). , 2011, Blood.

[4]  F. Casale,et al.  Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants , 2011, Cancer Chemotherapy and Pharmacology.

[5]  S. Raimondi,et al.  Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Narayan,et al.  Evaluating Performance of a Decision Support System to Improve Methotrexate Pharmacotherapy in Children and Young Adults With Cancer , 2011, Therapeutic drug monitoring.

[7]  J. Harbott,et al.  Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 , 2010, Leukemia.

[8]  M. Valsecchi,et al.  Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia , 2010, Leukemia.

[9]  H. Sather,et al.  Long Term Results of the Children’s Cancer Group Studies for Childhood Acute Lymphoblastic Leukemia 1983–2002: a Children’s Oncology Group Report , 2009, Leukemia.

[10]  J. Downing,et al.  Long-term results of St. Jude Total Therapy studies 11, 12, 13A, 13B and 14 for childhood acute lymphoblastic leukemia , 2009, Leukemia.

[11]  Cheng Cheng,et al.  Treating childhood acute lymphoblastic leukemia without cranial irradiation. , 2009, The New England journal of medicine.

[12]  J. Shuster,et al.  Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. , 2007, Blood.

[13]  P. Adamson,et al.  Understanding and managing methotrexate nephrotoxicity. , 2006, The oncologist.

[14]  S. Urien,et al.  Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy , 2006, Cancer Chemotherapy and Pharmacology.

[15]  G. Henze,et al.  Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure , 2005, British Journal of Cancer.

[16]  B. Burkhardt,et al.  The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. , 2004, Blood.

[17]  C. Pui,et al.  Ponte di Legno Working Group: statement on the right of children with leukemia to have full access to essential treatment and report on the Sixth International Childhood Acute Lymphoblastic Leukemia Workshop , 2004, Leukemia.

[18]  R. Peto,et al.  CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Relling,et al.  International childhood Acute Lymphoblastic Leukemia workshop: Sausalito, CA, 30 November–1 December 2000 , 2001, Leukemia.

[20]  R. Gelber,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. , 2001, Blood.

[21]  M. Relling,et al.  Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia , 2000, Leukemia.

[22]  A. Look,et al.  Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study. , 1998, Leukemia & lymphoma.

[23]  N. Winick,et al.  Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  N. Draper,et al.  Applied Regression Analysis: Draper/Applied Regression Analysis , 1998 .

[25]  M. Relling,et al.  Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. , 1998, The New England journal of medicine.

[26]  M. Relling,et al.  Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. , 1997, Molecular pharmacology.

[27]  W. Hiddemann,et al.  Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. , 1994, Blood.

[28]  M. Relling,et al.  Patient characteristics associated with high-risk methotrexate concentrations and toxicity. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C. Pui,et al.  Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: long-term results of St Jude total therapy study X. , 1992, Leukemia.

[30]  B. Chabner,et al.  Cancer Chemotherapy: Principles and Practice , 1990 .

[31]  C. Pui,et al.  Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance , 1986, Clinical pharmacology and therapeutics.

[32]  W. Evans,et al.  Disposition of Intermediate-Dose Methotrexate in Children with Acute Lymphocytic Leukemia , 1982, Drug intelligence & clinical pharmacy.

[33]  S. Rosenberg,et al.  Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. , 1977, The New England journal of medicine.

[34]  W. Evans,et al.  Recovery from toxicity associated with high-dose methotrexate: prognostic factors. , 1977, Cancer treatment reports.

[35]  D. V. Von Hoff,et al.  Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. , 1977, Cancer treatment reports.

[36]  J. Lukas,et al.  Population Pharmacokinetics of High-Dose Methotrexate in Children with Acute Lymphoblastic Leukaemia , 2006, Clinical pharmacokinetics.

[37]  C. Pratt,et al.  Pharmacokinetic monitoring of high-dose methotrexate , 2004, Cancer Chemotherapy and Pharmacology.

[38]  N. Winick,et al.  A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial , 2001, Leukemia.

[39]  R. Gunst.  Applied Regression Analysis , 1999, Technometrics.

[40]  S. Bentzen,et al.  Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia--a logistic regression analysis. , 1998, Acta oncologica.

[41]  M. Relling,et al.  Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. , 1996, The Journal of clinical investigation.

[42]  M. Relling,et al.  Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. , 1994, Blood.

[43]  William J. Jusko,et al.  Berichten , 2005, Pharmaceutisch weekblad.